Executive Officers

Jonas Grossman, 46
Co-Founder, Chief Executive Officer, President, Secretary, Treasurer, and Director

Since April 2020, Mr. Grossman has been the chief executive officer and president of Chardan Healthcare Acquisition 2 Corp., a special purpose acquisition company. He was the chief Executive officer and president of Chardan Healthcare Acquisition Corp. from March 2018 until its merger in October 2019 with BiomX (NYSE: PHGE). Mr. Grossman is currently a director of BiomX. He was a co-founder and director for LifeSci Acquisition Corp., a special purpose acquisition company from March 2020 until its merger with Vincera Pharma, Inc. in December of 2020. Since December 2020, Mr. Grossman has served as a director of Ventoux CCM Acquisition Corp., a special purpose acquisition company. He has served as managing partner and head of capital markets for Chardan, a New York headquartered broker/dealer, since December 2003, and has additionally served as president of Chardan since September 2015. Since 2003, Mr. Grossman has overseen the Chardan’s investment banking and capital markets activities and initiatives. He has extensive transactional experience having led or managed more than 400 transactions during his tenure at Chardan. Since December 2006, Mr. Grossman has served as a founding partner for Cornix Advisors, LLC, a New York based hedge fund. From 2001 until 2003, Mr. Grossman worked at Ramius Capital Group, LLC, a global multi-strategy hedge fund where he served as Vice President and Head Trader. Mr. Grossman served as a director for Ideanomics, Inc. (formerly China Broadband, Inc.) (NASDAQ: IDEX) from January 2008 until November 2010. He holds a B.A. in Economics from Cornell University and an M.B.A. from NYU’s Stern School of Business. Mr. Grossman has served on the board of directors for UNICEF since December 2016.

Gbola Amusa, 47
Chief Scientific Officer

Dr. Gbola Amusa is presently Partner and Chief Scientific Officer within the Investment Banking Division at Chardan. He is responsible for advising disruptive healthcare companies on capital formation strategies, M&A, and other transactions. Dr. Amusa joined Chardan at the end of 2014 to focus on identifying companies that will generate exceptionally high long-term investment returns from creating and sharing in real value for society. While in Chardan’s Equity Research Department from 2014 through July 2021, Dr. Amusa’s coverage, top picks, and counter-consensus calls were all associated with exceptional alpha generation, with Dr. Amusa for example ranked #2 out of over 6,000 Wall Street analysts in 2019 for his stock-picking performance in a study by TipRanks. Dr. Amusa was previously Managing Director, Head of European Pharma Research, and Global Pharma & Biotech Coordinator at UBS, where he oversaw 25 analysts, and ultimately finished as the #1 ranked European pharma analyst in the Institutional Investor (II) Survey. Prior to UBS, Dr. Amusa was a Senior Research Analyst and Head of European Pharma research at Sanford Bernstein. He started his career in finance at Goldman Sachs as an Associate in the Healthcare Investment Banking Group, where he worked on large transactions including the Amgen/Immunex merger. Additionally, Dr. Amusa was previously a Healthcare Finance & Strategy Consultant working with governments, companies, leading foundations and think tanks. Dr. Amusa previously served as the Executive Chairman of Chardan Healthcare Acquisition Corp and Executive Chairman and Chief Science Officer of Chardan Healthcare Acquisition 2 Corp; he serves on the board of both target companies, BiomX, Ltd and Renovacor, Inc. respectively. Dr. Amusa’s views on healthcare have been cited by socially responsible investing (SRI), ESG and sustainability organizations like FSG/Shared Value Initiative, GMI Ratings and the ATM Index. Dr. Amusa earned his BSE with honors in biomedical engineering from Duke University, an MD from Washington University Medical School, and his MBA (GPA 4.0/4.0) from the University of Chicago, Booth School of Business.

Alex Weil, 49
Chief Financial Officer and Director Nominee

Mr. Weil has served as managing director and co-head of FinTech investment banking at Chardan, a New York headquartered broker/dealer, since March 2020 and as a director of Ventoux CCM Acquisition Corp., a special purpose acquisition company, since December 2020. Since April 2021, he has served as chief financial officer of Chardan NexTech Acquisition 2 Corp., and he has agreed to also serve on the board of directors. From January 2018 to March 2020, he served as managing director and head of insurtech investment banking at SenaHill Securities, LLC, a New York headquartered broker/dealer. From January 2013 to September 2017, Mr. Weil was a director at PricewaterhouseCoopers Inc., a network of firms providing assurance, advisory and tax services. Prior to 2012, Mr. Weil held positions as a director at Lazard Middle Market, LLC, an executive director at UBS Securities LLC and a director at Citigroup Global Markets Inc. Mr. Weil holds a B.A. in Business Administration from the University of Colorado, Boulder.

Board of Directors

Kerry Propper, 46
Co-Founder and Director Nominee (Chairman)

Mr. Propper was co-founder of Chardan and served as its chief executive officer and head of its investment bank from 2003 to 2015. He is a pioneer in the special purpose acquisition marketplace, as he was the executive vice president and director of the third-ever publicly listed special purpose acquisition company, Chardan China Acquisition Corp., and has been an executive or senior advisor for five additional special purpose acquisition companies. Since 2015 Mr. Propper has been the chairman of Chardan’s board of directors and the co-founder and managing partner of ATW Partners, a growth-focused investment firm. Since the inception of ATW Partners, Mr. Propper has invested approximately $90 million of capital through the ATW Partner’s fund and its affiliated opportunity vehicles across multiple geographies and sectors. Within HealthTech and FinTech, Mr. Propper has an extraordinary track record with 15 investments and average returns of over 100%. Mr. Propper is also the co-chairman of 340B Technologies, a healthcare technology group, and is on the board of China Networks International Holdings, a shell company, and China Cablecom Holdings Ltd., a joint-venture provider of cable television services in the Peoples Republic of China. Mr. Propper dedicates much of his time philanthropy and he is a founding member of Nadia’s Initiative. He also serves on the executive board for Voices of Rwanda, Yazda and Digital Citizens Fund and the board of trustees of the International Crisis Group. Mr. Propper earned his B.A. in Economics and International Studies from Colby College.

Todd Thomson, 60
Director Nominee

Todd Thomson is currently the chief operating officer and chief financial officer of Kairos Ventures, an early-stage investment firm. He is an accomplished operating executive and entrepreneur, having served as Citigroup chief financial officer for five years and as chief executive officer of Citigroup’s nearly $10 billion global wealth management division for more than two years. Mr. Thomson is a leading practitioner on mergers and acquisitions and business strategy, having led the acquisition and strategy efforts for Citigroup and GE Capital, as well as serving as advisor to Fortune 500 firms while at Bain & Co., Booz Allen Hamilton, and Barents Group. He has extensive investing experience as chief executive officer of Citigroup alternative investments, chairman of the Citigroup pension investment committee, chairman of the dynasty investment committee, and a member of the investment committees for the Davidson College and World Resources Institute endowments. Prior to joining Kairos Ventures, Mr. Thomson served as co-founder and chairman of Dynasty Financial Partners, or Dynasty, a leading investment and technology platform for sophisticated independent advisors. Founded by Mr. Thomson and his colleagues in 2010, Dynasty serves nearly 50 registered investment advisor firms nationally, with $50 billion under management. In addition to serving as chairman, Todd served in several operating roles since Dynasty’s founding, including chairing the investment committee, serving as chief investment officer, and designing and leading Dynasty Capital Strategies.

Perry Boyle, 57
Director Nominee

Mr. Boyle was with Point72 Asset Management, L.P., or Point 72, and Point 72 affiliates from 2004 through his retirement in March 2020. He helped lead Point72’s launch as a registered investment advisor, raising over $6 billion in external capital. He originally joined S.A.C. Capital Advisors in 2004 as the firm’s first director of research. In January 2013 he became head of equities and, in January 2015, he became head of discretionary investing at Point72. From June 2016 through December 2017 he served as the president and chief investment officer of Stamford Harbor Capital, L.P., a company owned by businessman Steven A. Cohen. He returned to Point72 in January 2018. In his various leadership roles at the firm, Mr. Boyle managed the long/short and macro portfolios. He created and led the firm’s professional development programs, including P72 Academy and the 9s Program, and helped drive the internationalization of the Point72, overseeing offices in London, Hong Kong, Tokyo and Singapore. Prior to joining S.A.C., Mr. Boyle was a founding partner of Thomas Weisel Partners from 2000 until 2004, and a managing director at Alex. Brown & Sons from 1992-2000. He began his career as an investment banker with Salomon Brothers Inc. Mr. Boyle is a member of the advisory board of the Center for a New American Security (CNAS), and a director of The US Friends of the International Institute for Strategic Studies (IISS). He was a 2018 and 2019 delegate from the IISS to the Shangri-La Dialogue in Singapore. He is a council member of the Hoover Institution and a Lionel Curtis member of Chatham House. Mr. Boyle helps lead the annual Ride For Our Vets, the major source of funding for the Connecticut Veterans Legal Center. He received his B.A. in Economics from Stanford University, his M.B.A. from Dartmouth College and a M.A. from the Fletcher School at Tufts University. He has lectured on investing at Brown, Yale, Dartmouth, Harvard, Cambridge and UNC, and delivered testimony to Congress on financial regulation.

Noor Sweid, 40
Director Nominee

Ms. Sweid has been the founder and general partner of Global Ventures, a Dubai-based venture capital firm, since 2018. She is a founder, investor, and operator. Identified by Forbes magazine as one of the “World’s Top 50 Women in Tech,” Ms. Sweid’s previous roles include chief investment officer at The Dubai Future Foundation from 2016 until 2017, and founder of ZenYoga studio chain (acquired by Cedarbridge) from 2006 until 2014. Furthermore, she was the first Arab woman to scale, conduct an initial public offering of and operate a public company in the MENA region, listing Depa PLC, an interior solutions company on the NASDAQ Dubai and the London Stock Exchange (DEPA:DU) for approximately US$1.1. billion in April 2008. Since 2018, Ms. Sweid has served as a board member for CDP, a an insurance company, Arrow Labs, a field workforces solutions company, MunchOn, a food delivery company, and since 2020, has served as a director for Tribal Credit, a FinTech company, and Ogram, a short-term staffing solutions company. All of those companies are Global Ventures’ portfolio companies. Additionally, Ms. Sweid has been the chairperson of the Middle East Venture Capital Association since 2018, a director for MIT Sloan since 2017, a director for TechWadi since 2017, and a director of The Grooming Company Holding since 2016. Ms. Sweid has also been the independent chairperson of the board for Clue Health since 2020. Ms. Sweid holds a bachelors’ degrees in Finance and Economics from Boston College, an MBA from MIT Sloan, and began her career as a biotechnology and pharmaceutical strategy consultant in the US. She is a fellow of the inaugural class of the Finance Leaders Fellowship and a member of the Aspen Global Leadership Network, and is recognized as a Young Global Leader by the World Economic Forum.

Bryan Mazlish, 48
Director Nominee

Mr. Mazlish currently serves as chief executive officer of Surf Bio, Inc., a biotech company that he co-founded in 2021. Prior to this, he served as chief executive officer of a medical device startup, PhysioLogic Devices, Inc. from July, 2020 to October, 2020. From November, 2014 through June 2020, Mr. Mazlish served as chief technology officer, chief product officer, and president of Bigfoot Biomedical, Inc., or Bigfoot, a medtech company focused on diabetes care. Mr. Mazlish is a co-founder of Bigfoot and has served on its board of directors from its founding in November, 2014 through the present. Bigfoot acquired Smartloop LLC, the company he founded in 2012, to develop automated insulin delivery systems. In 2012, Mr. Mazlish transitioned from his former field in quantitative finance to life sciences work following a health diagnosis in his family. In 2005, he founded Overlook Capital, LLC, or Overlook, a proprietary trading, automated stock trading business. Mr. Mazlish successfully built and operated Overlook from 2005 to 2012. Prior to Overlook, Mr. Mazlish served as a managing director at Citigroup where he was responsible for the global equity derivative and U.S. portfolio trading desks. Mr. Mazlish received an B.A. from Harvard College where he graduated magna cum laude in computer science.

Colleen DiClaudio, 43
Director Nominee

Ms. DiClaudio currently serves as president of 340B Technologies, dba Nuvem, a 340B software solutions healthcare technology company she founded in August 2014. From June 2009 through August 2014 she served as vice president of business development of CompleteCare Health Network, located in New Jersey. Ms. DiClaudio received a master’s degree of public health from the University of Medicine and Dentistry of New Jersey in 2003 and a bachelor’s degree in Public Health from Stockton University in 2000.

Steven Rosenblatt, 45
Director Nominee

With more than 20 years of experience scaling startups and building technology companies in the digital and mobile ecosystem, Mr. Rosenblatt is a general partner at Oceans Ventures, a venture capital firm he co-founded in 2018. Prior to Oceans Ventures, Mr. Rosenblatt was President of Foursquare from 2016 until 2018. During his six-year tenure at the location intelligence company, he was responsible for transitioning the company from a purely consumer-facing location platform into an enterprise business, building a multi-product strategy and growing revenue by more than 70x. Mr. Rosenblatt’s role entailed overseeing all aspects of strategy, implementing the company’s revenue streams, and overseeing its biggest customers. During his time at Foursquare, the company earned numerous awards and accolades, including being named in CNBC’s Disruptor 50 list as one of the most disruptive tech companies in the world, being named in Deloitte’s Technology Fast 500 as one of the fastest-growing technology companies in North America, and being listed as one of Ad Age’s Best Places to work.  Before joining Foursquare, he launched iAd, Apple’s advertising platform for brands and developers, where he managed sales, agency relations, and the creative and strategy team from 2010 until 2012.  Mr. Rosenblatt led the opening of Apple’s New York office and worked closely with leadership teams to build a presence in New York. Prior to this, Mr. Rosenblatt served as Senior Vice President of Advertising Sales at Quattro Wireless from January 2008, until it was acquired by Apple in January 2010. He is a proud graduate of the University of Michigan.

.